Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid symbols : Pfe save search
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
Published: 2022-03-15 (Crawled : 23:00) - globenewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: 1.63%
H: 11.55%
C: 11.21%
covid-19 covid authorization vaccine tiona merge order emergency use authorization
Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
Published: 2022-03-09 (Crawled : 13:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 1.28%
H: 2.26%
C: 1.29%
covid-19 treatment phase 2 phase 2/3 covid
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
Published: 2022-01-03 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.93%
H: 0.09%
C: -3.16%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -1.52%
H: 0.89%
C: -8.67%
covid-19 fda als covid authorization vaccine merge order emergency use authorization
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
Published: 2021-12-22 (Crawled : 20:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.51%
H: 2.25%
C: 0.51%
covid-19 treatment fda covid authorization antiviral merge emergency use authorization
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Published: 2021-12-22 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.51%
H: 2.25%
C: 0.51%
covid-19 treatment covid antiviral
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 risk phase 2/3 covid antiviral results
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
Published: 2021-12-09 (Crawled : 18:00) - globenewswire.com
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
|
| O: 0.69%
H: 0.68%
C: 0.68%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -3.53%
H: 0.32%
C: -4.65%
covid-19 fda covid authorization vaccine merge order emergency use authorization
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
Published: 2021-12-07 (Crawled : 19:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
treatment covid antiviral vaccine covid-19
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Published: 2021-11-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: 0.49%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: 7.04%
H: 8.12%
C: 7.96%
covid vaccine phase 3 trial
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
Published: 2021-11-19 (Crawled : 13:30) - globenewswire.com
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
|
| O: -2.67%
H: 0.45%
C: 0.45%
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
|
| O: 3.28%
H: 0.0%
C: 0.0%
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
covid fda vaccine merge order emergency use authorization
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Published: 2021-11-18 (Crawled : 13:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 2.34%
H: 1.19%
C: 0.61%
covid treatment antiviral
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
Published: 2021-11-16 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
covid treatment antiviral patent license
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
Published: 2021-11-05 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 8.64%
H: 0.0%
C: 0.0%
covid treatment phase 2 risk phase 2/3 antiviral
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
Published: 2021-10-29 (Crawled : 22:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 77
|
Health Technology
| Email alert
Add to watchlist
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
| Email alert
Add to watchlist
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
| Email alert
Add to watchlist
covid fda children vaccine merge emergency use authorization
Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.05%
H: 1.68%
C: 0.54%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.83%
H: 1.2%
C: 0.32%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: 1.34%
H: 2.2%
C: 0.52%
covid vaccine
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years
Published: 2021-10-26 (Crawled : 23:00) - globenewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.39%
H: 0.23%
C: -1.13%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.91%
H: 0.06%
C: -1.04%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -0.4%
H: 1.16%
C: -5.35%
covid fda children vaccine merge emergency use authorization
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Published: 2021-10-21 (Crawled : 11:00) - globenewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.6%
H: 0.08%
C: -0.45%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: -0.08%
H: 0.41%
C: 0.41%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: 2.66%
H: 3.69%
C: 3.53%
covid vaccine phase 3 trial
Two in Three Parents of Children Ages 5-11 Plan to Vaccinate Their Child Against COVID-19
Published: 2021-10-14 (Crawled : 10:00) - prnewswire.com
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: 0.34%
H: 0.95%
C: 0.26%
JNJ | News | $149.12 0.82% 0.3% 7.2M
|
Health Technology
|
| O: 0.32%
H: 0.9%
C: 0.25%
covid children vaccine
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
SNY | News | $47.15 1.84% 1.75% 2M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
BNTX | News | $88.01 1.38% 1.36% 340K
|
Health Technology
|
| O: -4.36%
H: 1.09%
C: -5.85%
covid fda children vaccine trial
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
Published: 2021-09-27 (Crawled : 11:00) - biospace.com/
PFE | News A | $26.26 1.0% 0.38% 29M
|
Health Technology
|
| O: -0.34%
H: 0.48%
C: -0.8%
covid phase 2 phase 2/3 antiviral
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.